Sign in
Taking people in United StatesPhase 2

Dupilumab for alopecia areata in people with allergy-related conditions or high IgE

Tests dupilumab against placebo in adults with alopecia areata and allergic background.

Key facts

Who runs it
Emma Guttman
Where
Irvine, New York, and Rochester, United StatesSee the 3 sites
Trial code
Registry title
Regeneron AA Multicenter (Dupilumab)
Status
Recruiting
Phase
Phase 2
People taking part
76 people, planned
Started
10 Apr 2023
Expected to end
31 Oct 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dupilumab
  • Placebo
Record updated
17 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe alopecia areata (patchy hair loss) who have a high IgE level and/or a personal or family history of allergy (atopy).

Age
18 years and older
Sex
Male and female
Disease stage
At least 6 months of moderate to severe alopecia areata with ≥ 50% of the scalp affected (SALT score), or ≥ 95% scalp hair loss (alopecia totalis or universalis). Some hair regrowth must have happened within 7 years of the last hair loss episode.
Earlier treatment
People cannot join if they were treated with dupilumab before. No systemic immune-suppressing drugs or UV light therapy within 4 weeks before randomization. No oral JAK inhibitor within 12 weeks before baseline. No topical corticosteroids, tacrolimus or pimecrolimus within 1 week before baseline.
Biomarker or test result
Screening IgE > 200 and/or personal or family history of atopy. Blood tests must be within set limits, for example white blood cells ≥ 3000/mm3 and hemoglobin ≥ 10 g/dL.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Hair loss from another cause, or no hair regrowth for ≥ 7 years
  • Severe uncontrolled asthma or life-threatening asthma attacks
  • Active infection, weak immune system, active hepatitis B, hepatitis C, HIV or tuberculosis
  • Cancer within 5 years, except fully treated in situ non-melanoma skin and cervical cancers

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Male or female subjects who are at least 18 years old at the time of informed consent
  • Subject is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures
  • Subject is able to adhere to the study visit schedule and other protocol requirements
  • Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product (IP), FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:; Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy, OR; Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide
  • If subject is a female of non-childbearing potential, she must have documented history of infertility, be in a menopausal state for one year, or had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy
  • Subject has a history of at least 6 months of moderate to severe AA (≥ 50% scalp involvement) as measured using the SALT score; OR subject has ≥ 95% loss of scalp hair for enrollment as AA totalis (AT) or universalis (AU) subtypes
  • Subject has a screening IgE > 200 and/or personal and/or familial history of atopy
  • Subjects must meet the following laboratory criteria:; White blood cell count ≥ 3000/mm3 (≥ 3.0 x 109/L) and < 14,000/mm3 (≤ 14 x 109/L); Platelet count ≥ 100,000/μL (≥ 100 x 109/L); Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L); AST (SGOT) and ALT (SGPT) ≤ 2 x upper limit of normal (ULN). If the initial test shows ALT or AST > 2 times the ULN, one repeat test is allowed during the Screening Phase; Total bilirubin ≤ 2 mg/dL (34 μmol/L). If the initial test shows total bilirubin > 2 mg/dL (34 μmol/L), one repeat test is allowed during the Screening Phase; Hemoglobin ≥ 10 g/dL (≥ 6.2 mmol/L)
  • Subject is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing

Who cannot take part

  • Subject's cause of hair loss is indeterminable and/or they have concomitant causes of alopecia, such traction, cicatricial, pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia (i.e. Ludwig Type III or Norwood-Hamilton Stage ≥ V)
  • Subject has a concurrent or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, intestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease
  • Subject has received a live attenuated vaccine ≤ 30 days prior to study randomization
  • Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, or ultraviolet (UV) phototherapy with/without Psoralen Ultraviolet A (PUVA) therapy within 4 weeks prior to randomization
  • Use of an oral JAK inhibitor (tofacitinib, ruxolitinib, baricitinib, or investigational oral JAK Inhibitors) within 12 weeks prior to the Baseline visit
  • Subject has been previously treated with dupiliumab
  • Subject has used topical corticosteroids, and/or tacrolimus, and/or pimecrolimus within 1 week before the Baseline visit
  • Subject currently uses or plans to use anti-retroviral therapy at any time during the study
  • Severe, uncontrolled asthma or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic mediations
  • Subject has an active bacterial, viral, or helminth parasitic infections; OR a history of ongoing, recurrent severe infections requiring systemic antibiotics
  • Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology or active or untreated latent tuberculosis at the time of screening for subjects determined by the investigators to be at high-risk for this disease
  • Subject has a suspected or active lymphoproliferative disorder or malignancy; OR a history of malignancy within 5 years before the Baseline assessment, except for completely treated in situ non-melanoma skin and cervical cancers without evidence of metastasis
  • Subject has any other medical or psychological condition that, in the opinion of the investigator, may present additional unreasonable risks as a result of their participation in the study and/or interfere with clinic visits and necessary study assessments
  • History of adverse systemic or allergic reactions to any component of the study drug
  • Severe, untreated asthma or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic mediations
  • Subject has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints
  • Subject has a history of AA with no evidence of hair regrowth for ≥ 7 years since their last episode of hair loss
  • The presence of any of the following will exclude a subject from enrollment:
  • Subject is pregnant or breastfeeding
  • Subject with a known or suspected underlying immunodeficiency or immune-compromised state as determined by the investigator

Where in United States

  • University of California, IrvineIrvine, United StatesContact: Jamy PaniaguaTaking people
  • Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Giselle SingerTaking people
  • UR Dermatology at College TownRochester, United StatesContact: Alicia PapaliaTaking people

About the trial

What the trial wants to find out

This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of atopy.

Read full original descriptionShow less

Subjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).

The 2 groups in the trial

  • DupilumabTreatment being tested

    Dupilumab: weekly 300mg SC injections Manufacturer: Regeneron

  • PlaceboPlacebo, for comparison

    Placebo: weekly SC injections of equivalent volume Manufacturer: Regeneron

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and/or High IgE
Plain-language title
Dupilumab for alopecia areata in people with allergy-related conditions or high IgEGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
17 June 2026